Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models

  • Alvarez-Perez, Juan Carlos
  • Sanjuan-Hidalgo, Juan
  • Arenas, Alberto M.
  • Hernandez-Navas, Ivan
  • Benitez-Cantos, Maria S.
  • Andrades, Alvaro
  • Calabuig-Farinas, Silvia
  • Paz-Ares, Luis
  • Ferrer, Irene
  • Medina, Pedro P.
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] Missense mutations in the 12th codon of KRAS are key drivers of lung cancer, with glycine-to-cysteine (G12C) and glycine-to-aspartic acid (G12D) substitutions being among the most prevalent. These mutations are strongly associated with poor survival outcomes. Given the critical role of KRAS in lung cancer and other cancers, it remains as a major target for the development of new and complementary treatments. We have developed a CRISPR-High Fidelity (HiFi)-Cas9-based therapy strategy that can effectively and specifically target KRASG12C and KRASG12D mutants, avoiding KRASWT off-targeting and affecting KRAS downstream pathways, thereby significantly reducing tumorgenicity. The delivery of HiFiCas9 components via ribonucleoprotein particles (RNPs) and adenovirus (AdV) effectively abrogates cell viability in KRAS-mutant Non-Small Cell Lung Cancer (NSCLC) preclinical models, including 2D and 3D cell cultures, cell-derived xenografts (CDX), and patient-derived xenograft organoids (PDXO). Our in vitro studies demonstrate that HiFiCas9-based therapy achieves superior KRAS inhibition compared to Sotorasib and effectively circumvents certain resistance mechanisms associated with Sotorasib treatment. Moreover, in vivo delivery using adenoviral particles significantly suppresses tumor growth in preclinical NSCLC models. Collectively, our findings establish HiFiCas9 as an effective therapeutic strategy with promising clinical applications, especially if in vivo delivery methods are further optimized., P.P.M.'s laboratory is supported by the grants PID2021-126111OB-I00 and PID2024-159252OB-I00, funded by the MCIN/AEI/10.13039/501100011033 and by ERDF ("A way to make Europe"), the Spanish Association Against Cancer (LAB-AECC-2018), the Junta de Andalucia (PI-0203-2022 and PI-0228-2024), and the University of Granada (B-CTS-480-UGR20, C-EXP-051-UGR23, C-CTS-149-UGR23). J.S.-H. is supported by a grant from the Scientific Foundation of the Spanish Association Against Cancer in Granada (#PRDGR21428SANJ). J.C.A.-P. was supported by an MSCA-IF-EF-RI 837897 fellowship (Horizon 2020 Framework Programme). A.M.A. was supported by an FPU17/01258 fellowship. A.A. was supported by an FPU17/00067 fellowship (Spanish Ministry of Science, Innovation, and Universities) and by the Programa de Contratos Puente (Plan Propio 2022) of the University of Granada. M.S.B.-C. was supported by an FPU19/00576 fellowship (Spanish Ministry of Science, Innovation, and Universities). E.J.-L.'s laboratory is funded by the Spanish Association Against Cancer (PROYE18012ROSE), the Instituto de Salud Carlos III (PI22/01221), and CIBERONC (CB16/12/00350). We would like to thank Ms. Rosario Martin from Ecija for her donation to promote research into lung cancer. The authors acknowledge the support of the ROLUCAN Association (Rota Lucha Contra el Cancer) for facilitating this research, and the Ph.D program of Biochemistry and Molecular Biology of the University of Granada.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

PKP1 and MYC create a feedforward loop linking transcription and translation in squamous cell lung cancer

  • Boyero, Laura
  • Martín-Padrón, Joel
  • Fárez-Vidal, María Esther
  • Rodríguez, Maria Isabel
  • Andrades, Álvaro
  • Peinado, Paola
  • Arenas, Alberto M.
  • Ritoré-Salazar, Félix
  • Álvarez-Pérez, Juan Carlos
  • Cuadros, Marta
  • Medina, Pedro P.
[Purpose] Plakophilin 1 (PKP1) is well-known as an important component of the desmosome, a cell structure specialized in spot-like cell-to-cell adhesion. Although desmosomes have generally been associated with tumor suppressor functions, we recently found that PKP1 is recurrently overexpressed in squamous cell lung cancer (SqCLC) to exert an oncogenic role by enhancing the translation of MYC (c-Myc), a major oncogene. In this study, we aim to further characterize the functional relationship between PKP1 and MYC., [Methods] To determine the functional relationship between PKP1 and MYC, we performed correlation analyses between PKP1 and MYC mRNA expression levels, gain/loss of function models, chromatin immunoprecipitation (ChIP) and promoter mutagenesis followed by luciferase assays., [Results] We found a significant correlation between the mRNA levels of MYC and PKP1 in SqCLC primary tumor samples. In addition, we found that MYC is a direct transcription factor of PKP1 and binds to specific sequences within its promoter. In agreement with this, we found that MYC knockdown reduced PKP1 protein expression in different SqCLC models, which may explain the PKP1-MYC correlation that we found. Conversely, we found that PKP1 knockdown reduced MYC protein expression, while PKP1 overexpression enhanced MYC expression in these models., [Conclusions] Based on these results, we propose a feedforward functional relationship in which PKP1 enhances MYC translation in conjunction with the translation initiation complex by binding to the 5’-UTR of MYC mRNA, whereas MYC promotes PKP1 transcription by binding to its promoter. These results suggest that PKP1 may serve as a therapeutic target for SqCLC., The CTS-993 group is funded by the Ministry of Economy of Spain (SAF2015-67919-R), the Junta de Andalucía (Pl-0245-2017, PIGE-0440-2019, PI-0135-2020, PIGE-0213-2020, P20-00688), the Plan propio de la Universidad de Granada (PPJIA2019-06, and B‐CTS‐126‐UGR18), an International Association for the Study of Lung Cancer (IASLC) Young Investigator Award 2017, and the Spanish Association for Cancer Research (LAB-AECC-2018). L.B, J.M-P, and D.J.G. were supported by a “Fundación Benéfica Anticáncer Santa Cándida y San Francisco Javier” predoctoral fellowship. L.B. is currently funded by the Ministry of Health and Social Welfare of Junta de Andalucía (RH-0051-2020). J.C.A.-P is a Marie Curie Postdoctoral Researcher (European Commission. H2020-MSCA-IF-2018 #837897). P.P. was supported by a PhD “La Caixa Foundation” LCF/BQ/DE15/10360019 Fellowship. A.A, A.M.A. and F.R-S were supported by a Spanish Ministry of Education, Culture and Sports FPU fellowship: FPU17/00067, FPU17/01258, and FPU19/05124., Peer reviewed